Date: 2017-02-22
Type of information: R&D agreement
Compound: specific small molecules for Auris Medical's AM-102 project
Company: Auris Medical (Switzerland) King's College London (UK)
Therapeutic area: Otorhinolaryngology
Type agreement: R&D - research
Action mechanism:
Disease: tinnitus
Details:
- • On October 23, 2015, Auris Medical announced a drug discovery collaboration with King's College London. Professor David E. Thurston of the Institute of Pharmaceutical Science will lead a team at King's to develop and optimize a range of specific small molecules for Auris Medical's AM-102 project. The AM-102 compounds bind to a novel, undisclosed drug target for treating certain types of tinnitus. The collaboration project draws on earlier work performed for Auris Medical by the Wolfson Centre for Age-Related Diseases at King's under the leadership of Professor Patrick Doherty and Dr Gareth Williams. Auris Medical aims to select a lead compound for further preclinical and subsequent clinical development. The drug target for AM-102 was identified and validated previously through a collaboration with another leading research institution. It is different from the drug target for AM-101, Auris Medical's late-stage investigational tinnitus treatment.
Financial terms:
Latest news:
- • On February 22, 2017, Auris Medical announced the extension of its collaboration with King's College London. The collaboration is focused on the discovery of small molecule compounds for a second generation tinnitus treatment. The collaboration has generated leads that have been tested in vitro and in vivo. This extension will allow for further development with the aim of selecting a lead compound for the AM-102 program by the end of 2017.
- The project builds on earlier work performed at King's for Auris Medical by Professor Pat Doherty and Dr. Gareth Williams. The AM-102 compounds bind to a novel, undisclosed drug target for treating certain types of tinnitus.
Is general: Yes
